Alimera Sciences Inc (ALIM)

[rancher64]

ALIM's EU Potential

Total number of diabetic patients in 6 European countries.

Austria : 400,000
Portugal: 900,000
France : 3,945,753
Spain : 3,635,946
Germany : 7,372,226
UK : 3,636,375

Total in 6 countries - 19,890,300. 10% gets DME, so total DME patients = approx 2M. ILUVIEN's 3 years cost could be somewhere $6,000 to $8,800 in EU - let's say average $7,000. If ALIM gets only 10% of market share, it will be 200,000 DME patients X $7,000 = $1.4B sales in 3 years = $466M annual revenue.

And that's only from 6 EU countries.

Now add USA, Middle East and Worlds Diabetic Capital India... gigantic potential of ILUVIEN. That's why the sales are growing at fast pace. The little dilution can't make any dent to the share price. Any pull back is a great buy for those who are long term investors.